Anthony Adamis
Direktor/Vorstandsmitglied bei EYEPOINT PHARMACEUTICALS, INC.
Vermögen: 782 677 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jay Duker | M | 66 | 8 Jahre | |
| Hugo Peris | M | - |
Spiral Therapeutics, Inc.
 Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | 8 Jahre |
| David Guyer | M | 64 |
Eyebiotech Ltd.
 Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 5 Jahre |
| Khurem Farooq | M | 57 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 5 Jahre |
| Nancy Lurker | F | 66 | 8 Jahre | |
| Göran Albert Ando | M | 75 | 6 Jahre | |
| Eugene de Juan | M | - |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | 8 Jahre |
| David Fellows | M | 67 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 4 Jahre |
| Karen Zaderej | F | 62 | 2 Jahre | |
| Kate Bingham | F | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | - |
| Frédéric Guerard | M | 51 |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | - |
| Sean Bohen | M | 58 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 4 Jahre |
| Srini Akkaraju Akkaraju | M | 56 |
Theia Therapeutics, Inc.
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | - |
| Jennifer Leonard | F | - | - | |
| Ron I. Honig | M | - | 6 Jahre | |
| Jennifer Cook | F | 58 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 4 Jahre |
| Kristen MacFarlane | F | 60 |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | - |
| John Landis | M | 71 | 6 Jahre | |
| Baker Keith | M | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021.
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 3 Jahre |
| Wendy DiCicco | F | 56 | 5 Jahre | |
| Adrienne Graves | M | 69 |
Retinal Degeneration Fund
| - |
| Mike Ross | M | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | - |
| Isabelle Lefebvre | F | - | 2 Jahre | |
| Peter Lachmann | M | - |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | - |
| Andreas Wallnoefer | M | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | - |
| Charles C. Wykoff | M | - |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | - |
| Arshad Khanani | M | - |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | - |
| Sarah Milsom | F | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 3 Jahre |
| Jean Bennett | M | - |
Retinal Degeneration Fund
| 2 Jahre |
| Russell Kelley | M | - |
Retinal Degeneration Fund
| - |
| Catherine Bowes Rickman | M | - |
Retinal Degeneration Fund
| 2 Jahre |
| Michael Pine | M | - | 2 Jahre | |
| Stuart Duty | M | 59 | 1 Jahre | |
| Ye Liu | M | 53 | 3 Jahre | |
| Scott Jones | M | 57 | 5 Jahre | |
| Guy Jean L. Savoir | M | - |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | - |
| Ian Clark | M | - |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 5 Jahre |
| Napoleone Ferrara | M | 67 |
Theia Therapeutics, Inc.
| - |
| David B. Brint | M | - |
Retinal Degeneration Fund
| - |
| Said Saim | M | 66 | 5 Jahre | |
| Richard D. van Doren | M | 47 |
Theia Therapeutics, Inc.
| - |
| José-Alain Sahel | M | 68 |
Retinal Degeneration Fund
| 2 Jahre |
| Mark Blumenkranz | M | 73 |
Retinal Degeneration Fund
| 1 Jahre |
| George Elston | M | 59 | 5 Jahre | |
| Warren S. Thaler | M | 61 |
Retinal Degeneration Fund
| 6 Jahre |
| Benjamin Yerxa | M | 58 |
Retinal Degeneration Fund
| 6 Jahre |
| Guy Nohra | M | 63 |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | - |
| Diamantis Xylas | M | - |
Spiral Therapeutics, Inc.
Spiral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Spiral Therapeutics, Inc. manufactures pharmaceutical products. The firm also develops therapies for inner ear disorders. The company was founded by Hugo Peris, Justin S. Hanes and Eugene de Juan in 2016 and is headquartered in San Francisco, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ronald Eastman | M | 71 | 4 Jahre | |
| Maha Katabi | M | 50 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 1 Jahre |
| Chris Hollowood | M | 50 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 6 Jahre |
| Renée Galá | F | 52 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 2 Jahre |
| Ian Clark | M | 62 | 3 Jahre | |
| Dario Paggiarino | M | 67 | 8 Jahre | |
| Dominic Schmidt | M | 42 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 3 Jahre |
| Wouter Joustra | M | 35 | 1 Jahre | |
| Janet Hopkins | M | 60 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 37 | 64,91% |
| Vereinigtes Königreich | 22 | 38,60% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Anthony Adamis
- Persönliches Netzwerk
